| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Molecular Medicine,
Pathology, and
Clinical Laboratory Science, Osaka University Medical School, Suita, Osaka, Japan;
§
RESTO, JST, and Department of Biophysics, Kyoto University, Sakyo, Kyoto, Japan; and
¶
Osaka University, Osaka, Japan
The Wilms’ tumor gene WT1 is expressed at high levels not only in acute myelocytic and lymphocytic leukemia and in chronic myelocytic leukemia but also in various types of solid tumors including lung cancers. To determine whether the WT1 protein can serve as a target Ag for tumor-specific immunity, three 9-mer WT1 peptides (Db126, Db221, and Db235), which contain H-2Db-binding anchor motifs and have a comparatively higher binding affinity for H-2Db molecules, were tested in mice (C57BL/6, H-2Db) for in vivo induction of CTLs directed against these WT1 peptides. Only one peptide, Db126, with the highest binding affinity for H-2Db molecules induced vigorous CTL responses. The CTLs specifically lysed not only Db126-pulsed target cells dependently upon Db126 concentrations but also WT1-expressing tumor cells in an H-2Db-restricted manner. The sensitizing activity to the Db126-specific CTLs was recovered from the cell extract of WT1-expressing tumor cells targeted by the CTLs in the same retention time as that needed for the synthetic Db126 peptide in RP-HPLC, indicating that the Db126-specific CTLs recognize the Db126 peptide to kill WT1-expressing target cells. Furthermore, mice immunized with the Db126 peptide rejected challenges by WT1-expressing tumor cells and survived for a long time with no signs of autoaggression by the CTLs. Thus, the WT1 protein was identified as a novel tumor Ag. Immunotherapy targeting the WT1 protein should find clinical application for various types of human cancers.
This article has been cited by other articles:
|
|
 |
|
  T. Osada, C. Y. Woo, M. McKinney, X. Y. Yang, G. Lei, H. G. LaBreche, Z. C. Hartman, D. Niedzwiecki, N. Chao, A. Amalfitano, et al. Induction of Wilms' Tumor Protein (WT1)-Specific Antitumor Immunity Using a Truncated WT1-Expressing Adenovirus Vaccine Clin. Cancer Res., April 15, 2009; 15(8): 2789 - 2796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L.J.M. Smits, Z. N. Berneman, and V. F.I. Van Tendeloo Immunotherapy of Acute Myeloid Leukemia: Current Approaches Oncologist, March 1, 2009; 14(3): 240 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chaise, S. L. Buchan, J. Rice, J. Marquet, H. Rouard, M. Kuentz, G. E. Vittes, V. Molinier-Frenkel, J.-P. Farcet, H. J. Stauss, et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance Blood, October 1, 2008; 112(7): 2956 - 2964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rezvani, A. S. M. Yong, B. N. Savani, S. Mielke, K. Keyvanfar, E. Gostick, D. A. Price, D. C. Douek, and A. J. Barrett Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia Blood, September 15, 2007; 110(6): 1924 - 1932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rezvani, J. M. Brenchley, D. A. Price, Y. Kilical, E. Gostick, A. K. Sewell, J. Li, S. Mielke, D. C. Douek, and A. J. Barrett T-Cell Responses Directed against Multiple HLA-A*0201-Restricted Epitopes Derived from Wilms' Tumor 1 Protein in Patients with Leukemia and Healthy Donors: Identification, Quantification, and Characterization Clin. Cancer Res., December 15, 2005; 11(24): 8799 - 8807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Doubrovina, M. M. Doubrovin, S. Lee, J.-H. Shieh, G. Heller, E. Pamer, and R. J. O'Reilly In vitro Stimulation with WT1 Peptide-Loaded Epstein-Barr Virus-Positive B Cells Elicits High Frequencies of WT1 Peptide-Specific T Cells with In vitro and In vivo Tumoricidal Activity Clin. Cancer Res., November 1, 2004; 10(21): 7207 - 7219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Oka, A. Tsuboi, T. Taguchi, T. Osaki, T. Kyo, H. Nakajima, O. A. Elisseeva, Y. Oji, M. Kawakami, K. Ikegame, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression PNAS, September 21, 2004; 101(38): 13885 - 13890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tsukahara, Y. Nabeta, S. Kawaguchi, H. Ikeda, Y. Sato, K. Shimozawa, K. Ida, H. Asanuma, Y. Hirohashi, T. Torigoe, et al. Identification of Human Autologous Cytotoxic T-Lymphocyte-Defined Osteosarcoma Gene That Encodes a Transcriptional Regulator, Papillomavirus Binding Factor Cancer Res., August 1, 2004; 64(15): 5442 - 5448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Alberta, G. M. Springett, H. Rayburn, T. A. Natoli, J. Loring, J. A. Kreidberg, and D. Housman Role of the WT1 tumor suppressor in murine hematopoiesis Blood, April 1, 2003; 101(7): 2570 - 2574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Scheibenbogen, A. Letsch, E. Thiel, A. Schmittel, V. Mailaender, S. Baerwolf, D. Nagorsen, and U. Keilholz CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia Blood, August 28, 2002; 100(6): 2132 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Makita, A. Hiraki, T. Azuma, A. Tsuboi, Y. Oka, H. Sugiyama, S. Fujita, M. Tanimoto, M. Harada, and M. Yasukawa Antilung Cancer Effect of WT1-specific Cytotoxic T Lymphocytes Clin. Cancer Res., August 1, 2002; 8(8): 2626 - 2631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. A. Elisseeva, Y. Oka, A. Tsuboi, K. Ogata, F. Wu, E. H. Kim, T. Soma, H. Tamaki, M. Kawakami, Y. Oji, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies Blood, May 1, 2002; 99(9): 3272 - 3279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gaiger, V. Reese, M. L. Disis, and M. A. Cheever Immunity to WT1 in the animal model and in patients with acute myeloid leukemia Blood, August 15, 2000; 96(4): 1480 - 1489. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
